Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Forte Biosciences Inc (NQ: FBRX )

39.02 -0.92 (-2.30%)
Official Closing Price Updated: 4:00 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,934
Open 40.17
Bid (Size) 38.61 (1)
Ask (Size) 39.02 (1)
Prev. Close 39.94
Today's Range 37.55 - 40.17
52wk Range 13.35 - 53.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting... 
From Business Wire News Releases
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock... 
From Business Wire News Releases

Performance

YTD
+10.66%
+10.66%
1 Month
-2.84%
-2.84%
3 Month
+15.72%
+15.72%
6 Month
+86.16%
+86.16%
1 Year
+132.26%
+132.26%

More News

Read More
Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
From Business Wire News Releases
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
From Business Wire News Releases
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
From Business Wire News Releases
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Business Wire News Releases
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
From Business Wire News Releases
Forte Biosciences Announces Proposed Public Offering of Common Stock
From Business Wire News Releases
Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis
From Business Wire News Releases
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
From Business Wire News Releases
Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.